Literature DB >> 8266077

Interleukin-2 receptor gamma chain: a functional component of the interleukin-7 receptor.

M Noguchi1, Y Nakamura, S M Russell, S F Ziegler, M Tsang, X Cao, W J Leonard.   

Abstract

The interleukin-2 receptor gamma chain (IL-2R gamma) is a necessary component of functional IL-2 receptors. IL-2R gamma mutations result in X-linked severe combined immunodeficiency (XSCID) in humans, a disease characterized by the presence of few or no T cells. In contrast, SCID patients with IL-2 deficiency and IL-2-deficient mice have normal numbers of T cells, suggesting that IL-2R gamma is part of more than one cytokine receptor. By using chemical cross-linking, IL-2R gamma was shown to be physically associated with the IL-7 receptor. The presence of IL-2R gamma augmented both IL-7 binding affinity and the efficiency of internalization of IL-7. These findings may help explain the defects of XSCID. Given its role in more than one cytokine receptor system, the common gamma chain (gamma c) is proposed as the designation for IL-2R gamma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8266077     DOI: 10.1126/science.8266077

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  194 in total

Review 1.  Interleukin-2 signaling and inherited immunodeficiency.

Authors:  N A Cacalano; J A Johnston
Journal:  Am J Hum Genet       Date:  1999-08       Impact factor: 11.025

Review 2.  Gene therapy of X-linked severe combined immunodeficiency.

Authors:  Salima Hacein-Bey-Abina; Alain Fischer; Marina Cavazzana-Calvo
Journal:  Int J Hematol       Date:  2002-11       Impact factor: 2.490

3.  Interleukin 7 receptor-deficient mice lack gammadelta T cells.

Authors:  K Maki; S Sunaga; Y Komagata; Y Kodaira; A Mabuchi; H Karasuyama; K Yokomuro; J I Miyazaki; K Ikuta
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

4.  Human lymphoid development in the absence of common γ-chain receptor signaling.

Authors:  Lisa A Kohn; Christopher S Seet; Jessica Scholes; Felicia Codrea; Rebecca Chan; Sania Zaidi-Merchant; Yuhua Zhu; Satiro De Oliveira; Neena Kapoor; Ami Shah; Hisham Abdel-Azim; Donald B Kohn; Gay M Crooks
Journal:  J Immunol       Date:  2014-04-25       Impact factor: 5.422

5.  Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy.

Authors:  Olivier Humbert; Frieda Chan; Yogendra S Rajawat; Troy R Torgerson; Christopher R Burtner; Nicholas W Hubbard; Daniel Humphrys; Zachary K Norgaard; Patricia O'Donnell; Jennifer E Adair; Grant D Trobridge; Andrew M Scharenberg; Peter J Felsburg; David J Rawlings; Hans-Peter Kiem
Journal:  Blood Adv       Date:  2018-05-08

6.  Evidence for a critical role for the cytoplasmic region of the interleukin 2 (IL-2) receptor gamma chain in IL-2, IL-4, and IL-7 signalling.

Authors:  A Kawahara; Y Minami; T Taniguchi
Journal:  Mol Cell Biol       Date:  1994-08       Impact factor: 4.272

7.  Signaling through the interleukin 2 receptor beta chain activates a STAT-5-like DNA-binding activity.

Authors:  S L Gaffen; S Y Lai; W Xu; F Gouilleux; B Groner; M A Goldsmith; W C Greene
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-01       Impact factor: 11.205

8.  Interleukin 4 signals through two related pathways.

Authors:  A Pernis; B Witthuhn; A D Keegan; K Nelms; E Garfein; J N Ihle; W E Paul; J H Pierce; P Rothman
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

9.  Similarities and differences in signal transduction by interleukin 4 and interleukin 13: analysis of Janus kinase activation.

Authors:  A D Keegan; J A Johnston; P J Tortolani; L J McReynolds; C Kinzer; J J O'Shea; W E Paul
Journal:  Proc Natl Acad Sci U S A       Date:  1995-08-15       Impact factor: 11.205

10.  Constitutive activation of a variant of the env-mpl oncogene product by disulfide-linked homodimerization.

Authors:  G Courtois; L Bénit; Y Mikaeloff; M Pauchard; M Charon; P Varlet; S Gisselbrecht
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.